Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated a unique frontal fibrosing alopecia-like presentation of alopecia areata, finding that patients experienced an insidious, chronic course with limited scalp hair regrowth, and showed a lower response to systemic corticosteroids compared to patchy alopecia areata.

This review discusses the effects of IGF-1 on hair follicle cell proliferation and differentiation, highlighting its roles in paracrine signaling, apoptosis prevention, and hair growth, but reports no new clinical results.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

This article discusses frontal fibrosing alopecia as a type of Lichen planopilaris marked by gradual hair loss at the front of the scalp but reports no new clinical results.

In a clinical phase I/IIa study, subcutaneous injections of the peptide FOL-005 increased hair growth by 8% and were safe for treating alopecia.

According to this study, systemic retinoids, specifically oral isotretinoin and acitretin, were more effective than finasteride in stabilizing the frontal hairline in female patients with frontal fibrosing alopecia, achieving treatment goals in over 70% of cases.

In this case report, a patient with frontal fibrosing alopecia and lichen planus responded well to treatment with alitretinoin, suggesting a potential therapeutic role for alitretinoin in similar cases.

This case study diagnosed a 60-year-old woman with frontal fibrosing alopecia after histopathological analysis showed characteristic scarring patterns in the hairline area.

This study found that apoptosis was more prevalent in hair follicles of women with female pattern hair loss, particularly in miniaturized follicles, and was associated with follicular inflammation.

This article discusses various forms of alopecia and introduces Biofibre® as a current technique for addressing hair loss, without reporting new clinical results.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

A young woman developed facial bumps before hair loss, which is unusual for her condition.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

This study concluded that in female pattern hair loss patients, CGF and i-PRF treatments were more effective than PRP in increasing target area hair count, with i-PRF having the lowest adverse event rate.

This case report highlights an atypical presentation of favus in an immunocompetent adult, where a psoriasiform plaque over the 'bindi' area was successfully treated with systemic itraconazole, achieving complete resolution without relapse. Simple stains proved essential for diagnosis in this resource-limited setting.

This study found that A-FABP serum levels were significantly higher in male patients with androgenetic alopecia compared to controls, and the authors concluded that A-FABP could serve as a biomarker for early detection of this condition.

This study highlights IGF-1's role in promoting hair follicle proliferation, vascularization, and growth, suggesting its potential as a treatment target for hair loss disorders like androgenetic alopecia, though more research on delivery methods and long-term effects is needed.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

The document concludes that automatic biofiber hair implant is a new method for improving hair growth.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This study in Asian females found that higher use of moisturizers and sunscreen among FFA patients may reflect appearance concerns rather than indicating a direct link to the disease mechanism.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This study observed that combining high-potency steroids with pimecrolimus might effectively stabilize hairline recession in frontal fibrosing alopecia patients.

This study found that finasteride delivered through a nano-transferosomal gel showed improved penetration through skin layers compared to a conventional gel, suggesting a potential alternative for oral administration.

This study explores the various properties of the flavonoid fisetin, highlighting its potential therapeutic applications due to its ability to modulate numerous biological pathways, suggesting benefits in conditions like inflammation, cancer, and neurodegenerative diseases.